Trial Activated for Enrollment

The following study has been recently activated for patient enrollment by the Cancer Center Clinical Trials Office (CTO). Please click on the study link below to be taken to details regarding the study on ClinicalTrials.gov. 

Protocol Title: STELLAR-002 A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors

PI: Oana Danciu, MD

Sponsor: Exelixis

For more information or questions about a study, please email [email protected] or call 312-355-5112.